Navigation Links
BioBDx to Present at the 2012 BioPharm America and AdvaMed MedTech Conferences in Boston

PLYMOUTH MEETING, Pa., Sept. 17, 2012 /PRNewswire/ -- BioBehavioral Diagnostics (BioBDx) announced today that Calvin Sumner M.D., chief medical officer and SVP of clinical development, will be presenting at the BioPharm America Conference taking place September 19-21, 2012 and Byron Hewett, chairman and CEO, will be presenting at the AdvaMed MedTech Conference taking place October 1-3, 2012, both in Boston, MA.

BioBDx manufactures and markets the Quotient® System, a tool that objectively measures brain functions related to deficits in response inhibition. The first FDA-cleared application of this platform technology is the objective measurement of hyperactivity, impulsivity and inattention as an aid in the assessment of attention-deficit hyperactivity disorder (ADHD). 

Dr. Sumner and Mr. Hewett will provide a company overview and update on the Quotient System during their presentations:

 Event:BioPharm America 2012 ConferenceDate: Friday, September 21, 2012 Time: 10:25 am ETLocation:Hancock Room; Westin Boston WaterfrontEvent:AdvaMed 2012 MedTech ConferenceDate: Tuesday, October 2, 2012 Time: 11:10 am ETLocation:Room 051; Boston Convention & Exhibition Center 

About the Quotient® ADHD TestThe Quotient® ADHD Test measures motion and analyzes shifts in attention state to give an objective picture of the core symptom areas of ADHD.  Clinicians use the Quotient® ADHD Test at the initial visit to assess severity of the three core symptoms of ADHD; hyperactivity, inattention and impulsivity.  Patients may be re-assessed periodically at follow-up visits to guide treatment plans.  The clinician integrates the Quotient® report with information from other assessment tools and the clinical evaluation to help guide the discussion on the treatment plan. For more information please visit:

About BioBehavioral Diagnostics CompanyBioBDx manufactures and markets the Quotient System, a tool that aids in the objective and accurate assessment of neural control functions related to deficits in inhibitory control.  We are dedicated to providing physicians, parents and patients high-value information to guide personalized strategies and enhance quality of life for patients with ADHD.  Our vision is to provide accurate tools for the diagnosis and management of neurological and psychiatric conditions, leading to a transformation of behavioral medicine.  Founded in 2006, BioBDx is a privately held company.

Contacts:BioBDxByron Hewett

Chairman and Chief Executive Officer


Byron_Hewett@BioBDx.comMedia/Investors:Tiberend Strategic Advisors, Inc.

Claire Sojda


SOURCE BioBehavioral Diagnostics Company
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. PROLOR Biotech To Present Data On Its Long-Acting Human Growth Hormone At International NeuroEndocrine Meeting
2. BioSpecifics Technologies Corp. To Present at UBS Global Life Sciences Conference
3. BioLife Solutions Announces Presentation at IBC Inaugural Cell Therapy Clinical Development Conference
4. Representatives Betty McCollum (MN) and Steven LaTourette (OH) to Receive USGS Coalition Leadership Award
5. Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference
6. Cempra Inc. Presents Additional Data on the Clinical Profile and Activity Spectrum of Solithromycin at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
7. Lexicon Pharmaceuticals To Present At The Morgan Stanley Global Healthcare Conference
8. Isis Pharmaceuticals To Present At Two Upcoming Investor Conferences
9. AtheroNova to Present at Rodman & Renshaw 14th Annual Healthcare Conference in New York City
10. Onyx Pharmaceuticals To Present At Upcoming Investor Conferences
11. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... InSphero AG , ... 3D cell culture models, has launched a 14 Day Hepatotoxicity Testing Service ... InSightâ„¢ Human Liver Microtissues. The service streamlines toxicity testing of compounds in ...
(Date:10/13/2015)... 2015 ARRY ), Avanex Life ... JUNO ), and Progenix Pharmaceuticals, Inc. (NASDAQ: PGNX ... Corp. (OTCQX: AVXLD), Juno Therapeutics, Inc. (NASDAQ: JUNO ... --> Cooperative research and development efforts with ... lead to advancements in the treatment of severe wounds. ...
(Date:10/13/2015)... , Oct. 13, 2015  According to ... services will reach $102 billion by the end ... of the health industry, as it is estimated ... result of laboratory tests. In addition to diagnosing ... to evaluate disease progression, monitor drug treatment and ...
(Date:10/13/2015)... ... October 13, 2015 , ... Proove Biosciences, a ... their partnership with the Keck Medicine of the University of Southern California ... T.R.O.J.A.N. Study (Therapeutic Evaluation to Research Clinical Objectives Linking Genotypic and Phenotypic Association ...
Breaking Biology Technology:
(Date:10/6/2015)... Calif. , Oct. 6, 2015  Maverix ... today announced enhancements to its software portfolio with ... analysis kit for differential expression in eukaryotes. The ... which is a cloud-based genomic analysis solution that ... scientific discovery from next-generation sequencing efforts. ...
(Date:10/2/2015)... -- ) has announced ... Using Biometrics" report to their offering. ... of the "Enforcing the Law Using Biometrics" ... Research and Markets ( ) has announced ... Using Biometrics" report to their offering. ...
(Date:9/30/2015)... -- With nearly 300,000 Americans living with spinal cord injuries ... reach 12,500 annually, the role of Independent Living Centers ... Living (SCRS-IL) is increasingly important. SCRS-IL is one ... opening doors to independence for individuals with SCIs by ... technology services and education. "In serving people ...
Breaking Biology News(10 mins):